Fig. 5.
Fig. 5. FLT3W51/PML-RARα leukemias respond to ATRA. / Cohorts of histocompatible healthy FVB/N mice were sublethally irradiated and injected with 1 × 106 leukemic cells (n = 5 for all cohorts). (A) ATRA or placebo pellets (10 mg, 21-day release) were implanted on day 12 after injection. (B) ATRA or placebo pellets (10 mg, 21-day release) were implanted on day 6 after injection. Placebo versus ATRA, P = .002 (by log-rank).

FLT3W51/PML-RARα leukemias respond to ATRA.

Cohorts of histocompatible healthy FVB/N mice were sublethally irradiated and injected with 1 × 106 leukemic cells (n = 5 for all cohorts). (A) ATRA or placebo pellets (10 mg, 21-day release) were implanted on day 12 after injection. (B) ATRA or placebo pellets (10 mg, 21-day release) were implanted on day 6 after injection. Placebo versus ATRA, P = .002 (by log-rank).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal